# Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

Study · id `cardio:ct-nct07852637` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07852637](<https://clinicaltrials.gov/study/NCT07852637>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07852637

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 2300 participants.

## Technical summary

Registry record NCT07852637. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2300 participants (planned count; ClinicalTrials.gov record NCT07852637, source copy `cardio:ctgov-nct07852637-2026-10-01`, retrieved 2026-10-31)
- Planned start: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT07852637, source copy `cardio:ctgov-nct07852637-2026-10-01`, retrieved 2026-10-31)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT07852637, source copy `cardio:ctgov-nct07852637-2026-10-01`, retrieved 2026-10-31)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07852637, source copy `cardio:ctgov-nct07852637-2026-10-01`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT07852637, source copy `cardio:ctgov-nct07852637-2026-10-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07852637-2026-10-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
- Acronym: NEXT-CAT
- Condition: Venous Thromboembolism
- Condition: Active Cancer
- Intervention (Drug): edoxaban
- Intervention (Drug): Apixaban
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER
- Collaborator: Seoul National University Hospital
- Collaborator class: OTHER
- Collaborator: National Cancer Center, Korea
- Collaborator class: OTHER\_GOV
- Collaborator: Seoul St. Mary's Hospital
- Collaborator class: OTHER
- Collaborator: Dong-A University Hospital
- Collaborator class: OTHER
- Collaborator: Chonnam National University Hospital
- Collaborator class: OTHER
- Collaborator: Korea University Anam Hospital
- Collaborator class: OTHER
- Collaborator: Inje University Ilsan Paik Hospital
- Collaborator class: OTHER
- Collaborator: Konkuk University Hospital
- Collaborator class: OTHER
- Collaborator: Kangbuk Samsung Hospital, Sungkyunkwan University
- Collaborator class: OTHER
- Collaborator: Chung-Ang University Gwangmyeong Hospital
- Collaborator class: OTHER
- Collaborator: Chonbuk National University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)
- Registry lists this organization as a collaborator: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)
- Registry lists this organization as a collaborator: Seoul St. Mary's Hospital (`cardio:org-seoul-st-mary-s-hospital`)
- Registry lists this organization as a collaborator: Dong-A University Hospital (`cardio:org-dong-a-university-hospital`)
- Registry lists this organization as a collaborator: Chonnam National University Hospital (`cardio:org-chonnam-national-university-hospital`)
- Registry lists this organization as a collaborator: Korea University Anam Hospital (`cardio:org-korea-university-anam-hospital`)
- Registry lists this organization as a collaborator: Inje University Ilsan Paik Hospital (`cardio:org-inje-university-ilsan-paik-hospital`)
- Registry lists this organization as a collaborator: Chonbuk National University Hospital (`cardio:org-chonbuk-national-university-hospital`)

## Provenance

Content hash: 4ef8865500e8ee38c727d1a3df9c1820db5cdf909b27a4b850f6c5b3aea8b917
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
